A New Era in Cancer Care - Augusta University Health
... and Gynecology and Chief of the Section of Gynecologic Oncology. His clinical and research interests include ovarian cancer, cervix cancer and chemotherapy trials. Dr. Anand P. Jillella, Hematology/Oncology. Dr. Jillella is Professor of Medicine, and Chief of the Division of Hematology/Oncology and ...
... and Gynecology and Chief of the Section of Gynecologic Oncology. His clinical and research interests include ovarian cancer, cervix cancer and chemotherapy trials. Dr. Anand P. Jillella, Hematology/Oncology. Dr. Jillella is Professor of Medicine, and Chief of the Division of Hematology/Oncology and ...
Curriculum Vitae - Nihal E. Mohamed
... beliefs, expectations, and usage patterns of pharmaceuticals and other interventions to treat their ED will change as a result of learning their EndoPAT 2000 test scores. Role: Co-Investigator ...
... beliefs, expectations, and usage patterns of pharmaceuticals and other interventions to treat their ED will change as a result of learning their EndoPAT 2000 test scores. Role: Co-Investigator ...
Global Press Release
... the impact that cancer has. World Cancer Day is a chance to reflect on what you can do, make a pledge and take action. For more information on how to get involved, please visit: www.worldcancerday.org About the Union for International Cancer Control (UICC) UICC is the largest international cancer-fi ...
... the impact that cancer has. World Cancer Day is a chance to reflect on what you can do, make a pledge and take action. For more information on how to get involved, please visit: www.worldcancerday.org About the Union for International Cancer Control (UICC) UICC is the largest international cancer-fi ...
Simultaneous F Choline Positron Emission Tomography/Magnetic
... Diffusion-weighted imaging was without restriction of water diffusion (score, 1). The PET results demonstrated no focal elevated choline uptake. On the basis of these results, we concluded that there was no prostate carcinoma. In the follow-up period, the PSA level dropped to 2 ng/mL. Hence, a prost ...
... Diffusion-weighted imaging was without restriction of water diffusion (score, 1). The PET results demonstrated no focal elevated choline uptake. On the basis of these results, we concluded that there was no prostate carcinoma. In the follow-up period, the PSA level dropped to 2 ng/mL. Hence, a prost ...
Indicator 1 - Central Cancer Network
... standards by December 13 and undertake an audit against a tumour standard by March 13. (standard yet to be decided) ...
... standards by December 13 and undertake an audit against a tumour standard by March 13. (standard yet to be decided) ...
Press release in Word
... cervical cancer screening will be launched in January 2014. The main aim of the project is to increase the insufficient attendance of Czech citizens for screening examinations; therefore, those individuals will be invited who have not yet participated in the screening programmes and on that account ...
... cervical cancer screening will be launched in January 2014. The main aim of the project is to increase the insufficient attendance of Czech citizens for screening examinations; therefore, those individuals will be invited who have not yet participated in the screening programmes and on that account ...
The National Cancer Registry in Egypt A retrospective Cross
... 9 years. The cancer incidence rates are calculated based on population of Gharbia (as an indicator for rates in Egypt) and based on number of cases of each cancer type there. RESULTS: Breast cancer is considered to be the major cancer type with 18% (99% CI= 16.6%-19.4%) (n= 7332) share of total canc ...
... 9 years. The cancer incidence rates are calculated based on population of Gharbia (as an indicator for rates in Egypt) and based on number of cases of each cancer type there. RESULTS: Breast cancer is considered to be the major cancer type with 18% (99% CI= 16.6%-19.4%) (n= 7332) share of total canc ...
Endometrial (Uterine) Cancer
... Most experts divide endometrial adenocarcinomas into two types. ...
... Most experts divide endometrial adenocarcinomas into two types. ...
Height and Prostate Cancer Risk
... from cohort studies included in this meta-analysis, 19 reported on height or anthropometry as (one of) their primary exposure(s) in the abstract: 18 from the systematic review and the ProtecT nested case-control study. However, 12 articles, not mentioning height in the title or abstract, included re ...
... from cohort studies included in this meta-analysis, 19 reported on height or anthropometry as (one of) their primary exposure(s) in the abstract: 18 from the systematic review and the ProtecT nested case-control study. However, 12 articles, not mentioning height in the title or abstract, included re ...
Cancer - IIPRD
... course corrections of ongoing therapy (change of drug, dose, strategy, etc.) reflects a serious gap in increasing clinical efficacy based on realtime quantitative biochemical or pathological tests. The novel diagnostic kit developed fills this conspicuous gap as it can reliably and reproducibly de ...
... course corrections of ongoing therapy (change of drug, dose, strategy, etc.) reflects a serious gap in increasing clinical efficacy based on realtime quantitative biochemical or pathological tests. The novel diagnostic kit developed fills this conspicuous gap as it can reliably and reproducibly de ...
The level of evidence for the use of PSA and other biomarkers in the
... 13.8 per 100 000, respectively but the incidence is almost twice as high (118.3 and 64.0 per 100 000, respectively). This difference in the apparent incidence of prostate cancer may be explained by the fact that in France 50% of men ≥50 years have undergone PSA testing, compared with 10% in the UK. ...
... 13.8 per 100 000, respectively but the incidence is almost twice as high (118.3 and 64.0 per 100 000, respectively). This difference in the apparent incidence of prostate cancer may be explained by the fact that in France 50% of men ≥50 years have undergone PSA testing, compared with 10% in the UK. ...
Conquering Cancer Disparities: New Opportunities for
... evaluation of individual-level biomarkers and/or environmental exposures. However, to fully understand the causes of cancer disparities, a more comprehensive approach to the study of cancer causation and prevention may be required. Although cancer disparities have been described in the epidemiology ...
... evaluation of individual-level biomarkers and/or environmental exposures. However, to fully understand the causes of cancer disparities, a more comprehensive approach to the study of cancer causation and prevention may be required. Although cancer disparities have been described in the epidemiology ...
Queensland Prostate Cancer News
... In Australia, about 120,000 men have prostate cancer, and while most are diagnosed with localised prostate cancer, between 20-30 per cent progress to locally advanced or metastatic disease. A locally advanced tumour has spread beyond the prostatic capsule but is still confined to the prostate region ...
... In Australia, about 120,000 men have prostate cancer, and while most are diagnosed with localised prostate cancer, between 20-30 per cent progress to locally advanced or metastatic disease. A locally advanced tumour has spread beyond the prostatic capsule but is still confined to the prostate region ...
Follow-up after cancer treatment is complete
... Existing patients should already be identified by the DPIN system Pharmacare registration needed ...
... Existing patients should already be identified by the DPIN system Pharmacare registration needed ...
High-Risk Prostate Cancer: Local Therapy Matters
... with high-risk prostate cancer.5-7,11 Similarly, there has also been an OS benefit when EBRT was added to ADT.1, 2 Although combinations of RP plus EBRT or EBRT plus ADT have been associated with improved outcomes compared with monotherapy treatments, further improvement is needed for men with high- ...
... with high-risk prostate cancer.5-7,11 Similarly, there has also been an OS benefit when EBRT was added to ADT.1, 2 Although combinations of RP plus EBRT or EBRT plus ADT have been associated with improved outcomes compared with monotherapy treatments, further improvement is needed for men with high- ...
An expression signature at diagnosis to estimate prostate cancer
... accuracy of 70–80% for the prediction of biochemical or PSA recurrence, but these tools are less effective at predicting cancerspecific survival and even less accurate at predicting overall survival.1–6 It is known that PSA recurrence-free survival cannot be used as a reliable surrogate for PCa-speci ...
... accuracy of 70–80% for the prediction of biochemical or PSA recurrence, but these tools are less effective at predicting cancerspecific survival and even less accurate at predicting overall survival.1–6 It is known that PSA recurrence-free survival cannot be used as a reliable surrogate for PCa-speci ...
2016 Patient Brochure - Prostate Cancer Center of New Jersey
... Consultation Appointment Your first consultation appointment will take about an hour and consist of the ...
... Consultation Appointment Your first consultation appointment will take about an hour and consist of the ...
Update on the faster cancer treatment project November
... Faster cancer treatment project The faster cancer treatment project takes a patient pathway approach that covers surgical and non-surgical cancer treatment. The Government allocated $33 million over four years in Budget 2012 for the Ministry of Health (the Ministry) to implement the faster cancer tr ...
... Faster cancer treatment project The faster cancer treatment project takes a patient pathway approach that covers surgical and non-surgical cancer treatment. The Government allocated $33 million over four years in Budget 2012 for the Ministry of Health (the Ministry) to implement the faster cancer tr ...
Proteomic Profiling of Androgen-independent Prostate Cancer Cell
... however, the current screening methods are not able to differentiate between these two forms. Prostate-specific antigen is the most widely used biomarker for prostate cancer. However, due to a documented lack of specificity, it may also be elevated in other non-cancerous pathologies, including benig ...
... however, the current screening methods are not able to differentiate between these two forms. Prostate-specific antigen is the most widely used biomarker for prostate cancer. However, due to a documented lack of specificity, it may also be elevated in other non-cancerous pathologies, including benig ...